Lurasidone

General information

Indicated for: Lurasidone hydrochloride tablets are an atypical antipsychotic indicated for the treatment of: Schizophrenia in adults and adolescents (13 to 17 years) ( 1 , 14.1 ) Depressive episode associated with Bipolar I Disorder (bipolar depression) in adults and pediatric patients (10 to 17 years) as monotherapy ( 1 , 14.2 ) Depressive episode associated with Bipolar I Disorder (bipolar depression) in adults as adjunctive therapy with lithium or valproate ( 1 , 14.2 )

Dosing & forms

• Forms/strengths: —
• Frequency: —
• Food: —
• Typical range: 40–160 mg/day (with food)

Mechanism (brief)

D2 and 5‑HT2A antagonism; 5‑HT7 antagonism; 5‑HT1A partial agonism.

Metabolism & Half‑life

• Metabolism: CYP3A4 substrate, avoid strong inhibitors/inducers.
• Half‑life: ~18 h.

Therapeutic Drug Monitoring (TDM)

Recommended: No

Monitoring highlights

• Metabolic: weight, BMI, fasting lipids/glucose — Baseline, 3 mo, annually

In‑depth reading

• Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a network meta-analysis. — The Lancet Psychiatry (2023)
• Lurasidone in bipolar depression: meta‑analysis — Meta‑analysis (2020)

Sources

• Lurasidone label — DailyMed (2025)